ZyVersa Therapeutics Inc Stock Price, News & Analysis

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced the grant of inducement equity awards to two newly hired employees, effective March 8, 2023. The grants comprise nonqualified stock options to purchase a total of 13,000 shares at an exercise price of $2.26 per share, aligning with the closing price on that date. These options will vest in three annual installments starting March 8, 2024, contingent upon continued employment. ZyVersa focuses on developing first-in-class drugs for renal and inflammatory diseases, with products like VAR 200 targeting rare kidney diseases. The company emphasizes a commitment to addressing significant unmet medical needs.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) has announced the addition of Dr. Richard J. Glassock to its Renal Scientific Advisory Board, enhancing its commitment to developing innovative treatments for renal diseases. Dr. Glassock, an expert in glomerular disease, joins a team of distinguished advisors to advance the clinical development of VAR 200, a phase 2a-ready drug aimed at reducing renal lipid accumulation. The drug targets orphan kidney diseases, including focal segmental glomerulosclerosis (FSGS) and has shown promise in preclinical studies. ZyVersa aims to leverage this expertise to enhance its drug therapies for significant unmet medical needs in renal and inflammatory diseases.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced that CEO Stephen C. Glover will speak at the 33rd Annual Oppenheimer Healthcare Conference held virtually from March 13-15, 2023. During the event, Glover will discuss the development status of their Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200, aimed at treating renal diseases, and the inflammasome ASC inhibitor IC 100, targeting various CNS and inflammatory diseases. The conference aims to showcase ZyVersa's innovative product pipeline and potential for stockholder value. To learn more, a virtual one-on-one meeting with Glover can be arranged via the conference portal.

ZyVersa Therapeutics announced that CEO Stephen C. Glover will present key updates on its drug candidates during a fireside chat at the 35th Annual Roth Conference on March 14, 2023. The discussion will focus on the Cholesterol Efflux Mediator™ VAR 200, aimed at treating renal diseases, and the inflammasome ASC inhibitor IC 100, which targets various inflammatory diseases. The event will take place at The Ritz Carlton, Laguna Niguel, California.

ZyVersa, listed on Nasdaq as ZVSA, specializes in developing innovative therapies for conditions with significant unmet medical needs.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) recently highlighted research published in Translational Research, revealing that traumatic brain injury (TBI) enhances inflammasome activation in Alzheimer's disease (AD), worsening cognitive outcomes. It notes that individuals with a history of moderate TBI are 2.3 times more likely to develop AD, according to CDC data. The study asserts that IC 100, an inflammasome ASC inhibitor, significantly reduces this inflammatory response in AD models post-TBI. ZyVersa aims to leverage this data to advance its therapeutic approach targeting inflammasome-related neurological disorders.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced on January 27, 2023, the grant of an inducement equity award to its new Chief Medical Officer, Dr. Pablo Guzman. The grant includes a nonqualified stock option for 100,000 shares at an exercise price of $2.11 per share, the closing price on January 25, 2023. This award, approved by the Board’s Compensation Committee, vests in three equal installments over three years, contingent on Dr. Guzman's continued employment. ZyVersa focuses on developing first-in-class drugs for renal and inflammatory diseases, with notable projects including VAR 200 and IC 100.

ZyVersa Therapeutics (Nasdaq: ZVSA), a clinical stage biopharmaceutical company, will present at the BIO CEO & Investor Conference on February 6, 2023, at 2:45 PM EST in New York City. CEO Stephen C. Glover will discuss the development of two key clinical assets: VAR 200, aimed at renal diseases, and IC 100, targeting damaging inflammation. VAR 200 is in Phase 2a for treating focal segmental glomerulosclerosis and other kidney diseases, while IC 100 addresses inflammation in various diseases. This presentation highlights ZyVersa's strategy, achievements, and upcoming milestones, potentially impacting investor confidence.

ZyVersa Therapeutics (Nasdaq: ZVSA) announced a live webcast presentation by CEO Stephen C. Glover, scheduled for January 18, 2023, at 2:00 PM ET. The presentation will cover the company's advancements in its clinical programs for VAR 200, targeting renal diseases, and the potential of its inflammasome ASC inhibitor, IC 100.

The webcast will be available on ZyVersa's website, with a replay accessible for 90 days post-event. ZyVersa is focused on developing first-in-class therapies for patients with high unmet medical needs.

ZyVersa Therapeutics announced the appointment of three independent board members, expanding its board to seven. The new members include Gregory G. Freitag, J.D., CPA; Katrin Rupalla, PhD; and James Sapirstein. This strategic move aims to enhance the company’s leadership as it develops its lead drug candidates, VAR 200 for renal disease and IC 100 for inflammatory diseases. The board members bring extensive experience in the biopharmaceutical sector, with a strong focus on advancing clinical-stage products addressing significant unmet medical needs.